About DoMore Diagnostics
DoMore Diagnostics is transforming cancer care through artificial intelligence-powered digital pathology for clinical decision support. The company was established to meet the need for novel methods in precision medicine to personalize treatment for cancer patients, based on prominent research from leading institutions including Oslo University Hospital, Oxford University, and University College of London. The research project was selected as a Lighthouse project by the Norwegian Research Council to develop new diagnostic methods for cancer based on artificial intelligence, led by the late Prof. Håvard Danielsen with an aim to utilize new AI technology in digital pathology to reduce over- and undertreatment in cancer. The company's lead product, Histotype Px® Colorectal, is a CE-IVDD marked digital biomarker that leverages deep learning and digital pathology to predict patient outcomes and support more accurate, personalized treatment decisions in colorectal cancer (CRC). The solution addresses a major unsolved challenge in cancer care: the lack of reliable and affordable biomarkers to personalize treatment. In stage II and stage III CRC, surgery is often followed by adjuvant chemotherapy (ACT) in a one-size-fits-all approach, yet most patients are cured by surgery alone and ACT provides no benefit to the majority of patients (96-98% in stage II and 80% in stage III), only exposing them to short- and long-term side effects. Histotype Px® Colorectal is an advanced deep neural network algorithm for determining recurrence and survival prognosis in colorectal cancer based on routine H&E-stained histology slides. The algorithm is robust and based on solid ground truth and extensive training and testing with 4,500 patient samples and 90 million image tiles. The slides were prepared at several sites and scanned at two sites with two different scanners to ensure the test is robust and can be used in clinical practice. The solution provides accurate risk stratification, rapid turnaround time, seamless workflow integration, and complements and improves the accuracy of ctDNA testing. DoMore Diagnostics has received European Innovation Council (EIC) funding, combining grants and equity awarded up to €10 million in financing.
Mission & Story
Mission
To utilize new AI technology in digital pathology to reduce over- and undertreatment in cancer
Founding Story
DoMore Diagnostics was established based on prominent research from leading institutions like Oslo University Hospital, Oxford University and University College of London. The research project was selected as a Lighthouse project by the Norwegian Research Council to develop new diagnostic methods for cancer based on artificial intelligence. The project was led by the late Prof. Håvard Danielsen with an aim to utilize new AI technology in digital pathology to reduce over- and undertreatment in cancer.
Clinical Focus
Medical conditions and clinical areas addressed by DoMore Diagnostics.
Who It Serves
Milestones & Awards
Recent Milestones
Received European Innovation Council (EIC) Accelerator funding up to €10 million (grants up to €2.5 million combined with equity investments €0.5-€15 million). New US patent granted in May 2026 covering Histotype Px® methods including histological image analysis to predict patient outcomes. CE-IVDD certification for Histotype Px® Colorectal.
Awards & Recognition
Selected as Lighthouse project by Norwegian Research Council. Received European Innovation Council (EIC) Accelerator funding.
Key Partnerships
Social & Media
Latest Updates
Data from clinical validation in the Netherlands selected for oral presentation at ESMO 2025
Clinical Validation of Histotype Px Colorectal in U.S. Patients to be Presented at ESMO AI & Digital Oncology Congress 2025
DoMore Diagnostics Welcomes Audun Ljone Henriksen as our new AI Engineer
DoMore Diagnostics Welcomes Soroush Oskouei as AI Engineer
DoMore Diagnostics and Partners Announce Clinical Collaboration to Validate Histotype Px® Colorectal in Mexican Patients
Company Details
- Headquarters
- Oslo, Norway
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.